Voltalgan 3% cutaneous foam

Voltalgan is a topical anti-inflammatory medication containing diclofenac, specifically formulated as a cutaneous foam for rapid absorption. It is primarily used for the local treatment of pain and inflammation associated with muscle strains, sprains, and rheumatic conditions.

The brand has its roots in the pharmaceutical developments of Novartis, a major Swiss multinational. However, through various corporate restructurings and the formation of consumer healthcare joint ventures, the brand became part of the GlaxoSmithKline (GSK) Consumer Healthcare portfolio. In July 2022, GSK spun off its consumer healthcare division into a new independent company called Haleon. Today, Voltalgan is owned and managed by Haleon, which is headquartered in the United Kingdom and operates globally as a leader in consumer health.